Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.51 |
| ▸ | HTR2C | P28335 | 7/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325447 | 0.90 | HTR1A (0.49) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| SCHEMBL9684052 | 0.89 | HTR1A (0.48) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| SCHEMBL7767398 | 0.86 | PDE3B (0.50) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| SCHEMBL4882695 | 0.83 | HTR1A (0.51) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| SCHEMBL7332557 | 0.83 | HTR1A (0.51) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| SCHEMBL9684901 | 0.83 | PDE3B (0.51) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| Bromide SCHEMBL7797195 | 0.81 | HTR1A (0.50) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| SCHEMBL9685616 | 0.81 | HTR1A (0.60) | HTR1AHTR2CPDE3BPDE3APGR | |
| SCHEMBL1324801 | 0.80 | HTR1A (0.49) | HTR1AHTR2CCMA1PDE3BPDE3A | |
| SCHEMBL9685780 | 0.80 | HTR1A (0.50) | HTR1AHTR2CPDE3BPDE3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174011-B2 | Heterocyclic compounds, process for preparation of the same and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-06-08 | — | — | US | disclosed |
| EP-3115361-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015131856-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2015-09-11 | — | — | WO | disclosed |
| CN-104892589-A | Heterocyclic compound, preparation method therefor and use thereof | SHANGHAI INST MATERIA MEDICA | 2015-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174011-B2 | Heterocyclic compounds, process for preparation of the same and use thereof | CYP11B2, CYP11B1, ADCYAP1R1 | HTR1A 1013/4885HTR2C 333/4885CMA1 900/4885 |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | CYP11B2, CYP11B1, ADCYAP1R1 | HTR1A 1013/4885HTR2C 333/4885CMA1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.